{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:19:21Z","timestamp":1780046361335,"version":"3.53.1"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1212\/con.0000000000000415","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T09:31:58Z","timestamp":1481016718000},"page":"1978-2005","source":"Crossref","is-referenced-by-count":29,"title":["Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome"],"prefix":"10.1212","volume":"22","author":[{"given":"Michael W.","family":"Nicolle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"8","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mus.880120802","article-title":"AAEE Minimonograph #33: electrodiagnostic approach to defects of neuromuscular transmission","volume":"12","author":"Keesey JC","year":"1989","unstructured":"Keesey JC. AAEE Minimonograph #33: electrodiagnostic approach to defects of neuromuscular transmission. Muscle Nerve 1989;12(8):613\u2013626. doi:10.1002\/mus.880120802.","journal-title":"Muscle Nerve"},{"issue":"7","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp.43.7.601","article-title":"Mechanisms of acetylcholine receptor loss in myasthenia gravis","volume":"43","author":"Drachman DB","year":"1980","unstructured":"Drachman DB Adams RN Stanley EF Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry 1980;43(7):601\u2013610. doi:10.1136\/jnnp.43.7.601.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00127893-200201000-00002","article-title":"Myasthenia gravis","volume":"8","author":"Nicolle MW","year":"2002","unstructured":"Nicolle MW. Myasthenia gravis. Neurologist 2002;8(1):2\u201321.","journal-title":"Neurologist"},{"issue":"1","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/joa.12034","article-title":"The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis","volume":"224","author":"Koneczny I","year":"2014","unstructured":"Koneczny I Cossins J Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 2014;224(1):29\u201335. doi:10.1111\/joa.12034.","journal-title":"J Anat"},{"issue":"10","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.autrev.2014.08.037","article-title":"Cortactin: a new target in autoimmune myositis and Myasthenia Gravis","volume":"13","author":"Berrih-Aknin S","year":"2014","unstructured":"Berrih-Aknin S. Cortactin: a new target in autoimmune myositis and Myasthenia Gravis. Autoimmun Rev 2014;13(10):1001\u20131002. doi:10.1016\/j.autrev.2014.08.037.","journal-title":"Autoimmun Rev"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.011"},{"issue":"4","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"826\u2212834","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks S","year":"2016","unstructured":"Binks S Vincent A Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol 2016;263(4):826\u2212834. doi:10.1007\/s00415-015-7963-5.","journal-title":"J Neurol"},{"issue":"2","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30100-2","article-title":"The thymus in myasthenia gravis","volume":"12","author":"Hohlfeld R","year":"1994","unstructured":"Hohlfeld R Wekerle H. The thymus in myasthenia gravis. Neurol Clin 1994;12(2):331\u2013342.","journal-title":"Neurol Clin"},{"issue":"4","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton AE","year":"2015","unstructured":"Renton AE Pliner HA Provenzano C A genome-wide association study of myasthenia gravis. JAMA Neurol 2015;72(4):396\u2013404. doi:10.1001\/jamaneurol.2014.4103.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.11.049"},{"issue":"6","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu A","year":"2015","unstructured":"Nacu A Andersen JB Lisnic V Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 2015;48(6):362\u2013368. doi:10.3109\/08916934.2015.1030614.","journal-title":"Autoimmunity"},{"issue":"1","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE Nacu A Andersen JB Myasthenia gravis and risks for comorbidity. Eur J Neurol 2015;22(1):17\u201323. doi:10.1111\/ene.12599.","journal-title":"Eur J Neurol"},{"issue":"17","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad Z","year":"2011","unstructured":"Pakzad Z Aziz T Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76(17):1526\u20131528. doi:10.1212\/WNL.0b013e318217e735.","journal-title":"Neurology"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46"},{"issue":"10","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14(10):1023\u20131036. doi:10.1016\/S1474-4422(15)00145-3.","journal-title":"Lancet Neurol"},{"issue":"9","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"e106757","DOI":"10.1371\/journal.pone.0106757","article-title":"Insights into the classification of myasthenia gravis","volume":"9","author":"Akaishi T","year":"2014","unstructured":"Akaishi T Yamaguchi T Suzuki Y Insights into the classification of myasthenia gravis. PLoS One 2014;9(9):e106757. doi:10.1371\/journal.pone.0106757.","journal-title":"PLoS One"},{"issue":"8","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent A","year":"2003","unstructured":"Vincent A Clover L Buckley C Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74(8):1105\u20131108. doi:10.1136\/jnnp.74.8.1105.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3988\/jcn.2012.8.3.161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao ZF","year":"2012","unstructured":"Mao ZF Mo XA Qin C Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol 2012;8(3):161\u2013169. doi:10.3988\/jcn.2012.8.3.161.","journal-title":"J Clin Neurol"},{"issue":"5","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00314173","article-title":"Thymectomy in the treatment of myasthenia gravis: report of 247 patients","volume":"235","author":"Evoli A","year":"1988","unstructured":"Evoli A Batocchi AP Provenzano C Thymectomy in the treatment of myasthenia gravis: report of 247 patients. J Neurol 1988;235(5):272\u2013276. doi:10.1007\/BF00314173.","journal-title":"J Neurol"},{"issue":"5","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","article-title":"Clinical implementation of anti-acetylcholine receptor antibodies","volume":"56","author":"Somnier FE","year":"1993","unstructured":"Somnier FE. Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1993;56(5):496\u2013504. doi:10.1136\/jnnp.56.5.496.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s00415-006-0429-z","article-title":"Paraneoplastic diseases associated with thymoma","volume":"254","author":"Evoli A","year":"2007","unstructured":"Evoli A Minicuci GM Vitaliani R Paraneoplastic diseases associated with thymoma. J Neurol 2007;254(6):756\u2013762. doi:10.1007\/s00415-006-0429-z","journal-title":"J Neurol"},{"issue":"7","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia L","year":"2015","unstructured":"Nagia L Lemos J Abusamra K Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 2015;122(7):1517\u20131521. doi:10.1016\/j.ophtha.2015.03.010.","journal-title":"Ophthalmology"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x"},{"issue":"1","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1212\/01.wnl.0000223515.15691.26","article-title":"Sleep apnea in patients with myasthenia gravis","volume":"67","author":"Nicolle MW","year":"2006","unstructured":"Nicolle MW Rask S Koopman WJ Sleep apnea in patients with myasthenia gravis. Neurology 2006;67(1):140\u2013142. doi:10.1212\/01.wnl.0000223515.15691.26.","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jnnp.73.6.766","article-title":"Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome","volume":"73","author":"Wirtz PW","year":"2002","unstructured":"Wirtz PW Sotodeh M Nijnuis M Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73(6):766\u2013768. doi:10.1136\/jnnp.73.6.766.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.cnd.0000245218.70927.97","article-title":"Wrist and finger drop in myasthenia gravis","volume":"8","author":"Nicolle MW","year":"2006","unstructured":"Nicolle MW. Wrist and finger drop in myasthenia gravis. J Clin Neuromuscul Dis 2006;8(2):65\u201369. doi:10.1097\/01.cnd.0000245218.70927.97.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-2004-830903","article-title":"Myasthenia gravis: diagnostic mimics","volume":"24","author":"Engstrom JW","year":"2004","unstructured":"Engstrom JW. Myasthenia gravis: diagnostic mimics. Semin Neurol 2004;24(2):141\u2013147. doi:10.1055\/s-2004-830903.","journal-title":"Semin Neurol"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"issue":"7","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar M","year":"2006","unstructured":"Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16(7):459\u2013467. doi:10.1016\/j.nmd.2006.05.006","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1742-1241.2004.00053.x","article-title":"The place of the ice pack test in the diagnosis of myasthenia gravis","volume":"58","author":"Larner AJ","year":"2004","unstructured":"Larner AJ. The place of the ice pack test in the diagnosis of myasthenia gravis. Int J Clin Pract 2004;58(9):887\u2013888. doi:10.1111\/j.1742-1241.2004.00053.x.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders DB","year":"2003","unstructured":"Sanders DB El-Salem K Massey JM Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60(12):1978\u20131980. doi:10.1212\/01.WNL.0000065882.63904.53.","journal-title":"Neurology"},{"key":"e_1_3_1_33_2","volume-title":"Single fiber electromyography. Studies in healthy and diseased muscle","author":"Stalberg EV","year":"2010","unstructured":"Stalberg EV Trontelj J Sanders DB. Single fiber electromyography. Studies in healthy and diseased muscle. 3rd ed. Fiskeb\u00e4ckskil, Sweden: Edshagen Publishing House, 2010.","edition":"3"},{"issue":"9","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.0.CO;2-Y","article-title":"AAEM minimonograph #25: single-fiber electromyography","volume":"19","author":"Sanders DB","year":"1996","unstructured":"Sanders DB St\u00e5lberg EV. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve 1996;19(9):1069\u20131083. doi:10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.0.CO;2-Y.","journal-title":"Muscle Nerve"},{"issue":"2","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0317167100049040","article-title":"Usefulness of single fiber EMG for distinguishing neuromuscular from other causes of ocular muscle weakness","volume":"21","author":"Ukachoke C","year":"1994","unstructured":"Ukachoke C Ashby P Basinski A Usefulness of single fiber EMG for distinguishing neuromuscular from other causes of ocular muscle weakness. Can J Neurol Sci 1994;21(2):125\u2013128.","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.36.4.545","article-title":"Botulinum toxin for blepharospasm: single-fiber EMG studies","volume":"36","author":"Sanders DB","year":"1986","unstructured":"Sanders DB Massey EW Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986;36(4):545\u2013547. doi:10.1212\/WNL.36.4.545.","journal-title":"Neurology"},{"issue":"12","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent A","year":"1985","unstructured":"Vincent A Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48(12):1246\u20131252. doi:10.1136\/jnnp.48.12.1246.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan KH","year":"2007","unstructured":"Chan KH Lachance DH Harper CM Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36(5):651\u2013658. doi:10.1002\/mus.20854.","journal-title":"Muscle Nerve"},{"issue":"6","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz PM","year":"2015","unstructured":"Rodr\u00edguez Cruz PM Al-Hajjar M Huda S Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol 2015;72(6):642\u2013649. doi:10.1001\/jamaneurol.2015.0203.","journal-title":"JAMA Neurol"},{"issue":"4","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders DB","year":"2014","unstructured":"Sanders DB Burns TM Cutter GR Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 2014;49(4):483\u2013486. doi:10.1002\/mus.23944.","journal-title":"Muscle Nerve"},{"issue":"1","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/mus.23882","article-title":"Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?","volume":"49","author":"Choi Decroos E","year":"2014","unstructured":"Choi Decroos E Hobson-Webb LD Juel VC Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve 2014;49(1):30\u201334. doi:10.1002\/mus.23882.","journal-title":"Muscle Nerve"},{"issue":"1","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WCO.0b013e3282f4098e","article-title":"Ocular myasthenia: diagnostic and treatment recommendations and the evidence base","volume":"21","author":"Luchanok U","year":"2008","unstructured":"Luchanok U Kaminski H. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008;21(1):8\u201315. doi:10.1097\/WCO.0b013e3282f4098e.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cen3.12173","article-title":"Characteristics of myasthenia gravis with antibodies to muscle-specific kinase and low-density lipoprotein-related receptor protein 4","volume":"6","author":"Evoli A","year":"2015","unstructured":"Evoli A Iorio R. Characteristics of myasthenia gravis with antibodies to muscle-specific kinase and low-density lipoprotein-related receptor protein 4. Clin Exp Neuroimmunol 2015;6(1):40\u201348. doi:10.1111\/cen3.12173.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"9","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler DE","year":"2005","unstructured":"Stickler DE Massey JM Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005;116(9):2065\u20132068. doi:10.1016\/j.clinph.2005.06.003.","journal-title":"Clin Neurophysiol"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.01.011"},{"issue":"10","key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo E","year":"2014","unstructured":"Gallardo E Mart\u00ednez-Hern\u00e1ndez E Titulaer MJ Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014;13(10):1003\u20131007. doi:10.1016\/j.autrev.2014.08.039.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang B","year":"2014","unstructured":"Zhang B Shen C Bealmear B Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014;9(3):e91816. doi:10.1371\/journal.pone.0091816.","journal-title":"PLoS One"},{"issue":"5","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/j.crad.2014.01.005","article-title":"Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor","volume":"69","author":"Priola AM","year":"2014","unstructured":"Priola AM Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol 2014;69(5):e230\u2013e245. doi:10.1016\/j.crad.2014.01.005.","journal-title":"Clin Radiol"},{"issue":"10","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s004150050160","article-title":"Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases","volume":"244","author":"Batocchi AP","year":"1997","unstructured":"Batocchi AP Evoli A Majolini L Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases. J Neurol 1997;244(10):639\u2013645. doi:10.1007\/s004150050160","journal-title":"J Neurol"},{"issue":"6","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","article-title":"When the patient fails to respond to treatment: myasthenia gravis","volume":"7","author":"Hilton-Jones D","year":"2007","unstructured":"Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 2007;7(6):405\u2013411. doi:10.1136\/jnnp.2007.134130.","journal-title":"Pract Neurol"},{"issue":"4","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00041327-200312000-00001","article-title":"Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis?","volume":"23","author":"Kupersmith MJ","year":"2003","unstructured":"Kupersmith MJ. Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis? J Neuroophthalmol 2003;23(4):249\u2013250.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar M","year":"2016","unstructured":"Benatar M Mcdermott MP Sanders DB Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 2016;53(3):363\u2013369. doi:10.1002\/mus.24769.","journal-title":"Muscle Nerve"},{"issue":"17","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou A","year":"2010","unstructured":"Papaioannou A Morin S Cheung AM 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182(17):1864\u20131873. doi:10.1503\/cmaj.100771.","journal-title":"CMAJ"},{"issue":"4","key":"e_1_3_1_54_2","first-page":"CD005224","article-title":"Immunosuppressive agents for myasthenia gravis","author":"Hart IK","year":"2007","unstructured":"Hart IK Sathasivam S Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;(4):CD005224.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura E","year":"1985","unstructured":"Arsura E Brunner NG Namba T High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985;42(12):1149\u20131153. doi:10.1001\/archneur.1985.04060110031011.","journal-title":"Arch Neurol"},{"issue":"2","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold ME","year":"1974","unstructured":"Seybold ME Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974;290(2):81\u201384. doi:10.1056\/NEJM197401102900204.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.031"},{"issue":"6","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace J","year":"1998","unstructured":"Palace J Newsom-Davis J Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778\u20131783. doi:10.1212\/WNL.50.6.1778.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CND.0000000000000133","article-title":"A review of azathioprine-associated hepatotoxicity and myelosuppression in myasthenia gravis","volume":"18","author":"Jack KL","year":"2016","unstructured":"Jack KL Koopman WJ Hulley D A review of azathioprine-associated hepatotoxicity and myelosuppression in myasthenia gravis. J Clin Neuromusc Dis 2016;18(1):12\u201320. doi:10.1097\/CND.0000000000000133.","journal-title":"J Clin Neuromusc Dis"},{"issue":"3","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ene.12329","article-title":"Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine","volume":"21","author":"Pedersen EG","year":"2014","unstructured":"Pedersen EG Potteg\u00e5rd A Hallas J Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol 2014;21(3):454\u2013458. doi:10.1111\/ene.12329.","journal-title":"Eur J Neurol"},{"issue":"10","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"e00396","DOI":"10.1002\/brb3.396","article-title":"Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients","volume":"5","author":"McGurgan IJ","year":"2015","unstructured":"McGurgan IJ McGuigan C. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. Brain Behav 2015;5(10):e00396. doi:10.1002\/brb3.396.","journal-title":"Brain Behav"},{"issue":"6","key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/jcm4061229","article-title":"Cutaneous squamous cell carcinomas in organ transplant recipients","volume":"4","author":"Chockalingam R","year":"2015","unstructured":"Chockalingam R Downing C Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med 2015;4(6):1229\u20131239. doi:10.3390\/jcm4061229.","journal-title":"J Clin Med"},{"issue":"1","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill JT","year":"2011","unstructured":"Guptill JT Sanders DB Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44(1):36\u201340. doi:10.1002\/mus.22006.","journal-title":"Muscle Nerve"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.012"},{"issue":"5","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas CE","year":"1997","unstructured":"Thomas CE Mayer SA Gungor Y Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48(5):1253\u20131260. doi:10.1212\/WNL.48.5.1253.","journal-title":"Neurology"},{"key":"e_1_3_1_66_2","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos P","year":"2012","unstructured":"Gajdos P Chevret S Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012;12:CD002277. doi:10.1002\/14651858.CD002277.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06767.x"},{"issue":"5","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic","volume":"19","author":"Dhawan PS","year":"2015","unstructured":"Dhawan PS Goodman BP Harper CM IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic. Neurologist 2015;19(5):145\u2013148. doi:10.1097\/NRL.0000000000000026.","journal-title":"Neurologist"},{"issue":"1","key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.12.034","article-title":"IVIg in the chronic management of myasthenia gravis: is it enough for your money?","volume":"338","author":"Dalakas MC","year":"2014","unstructured":"Dalakas MC. IVIg in the chronic management of myasthenia gravis: is it enough for your money? J Neurol Sci 2014;338(1\u20132):1\u20132. doi:10.1016\/j.jns.2013.12.034.","journal-title":"J Neurol Sci"},{"issue":"5","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio R","year":"2015","unstructured":"Iorio R Damato V Alboini PE Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015;262(5):1115\u20131119. doi:10.1007\/s00415-014-7532-3.","journal-title":"J Neurol"},{"issue":"6","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/1756285615605700","article-title":"Future perspectives in target-specific immunotherapies of myasthenia gravis","volume":"8","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord 2015;8(6):316\u2013327. doi:10.1177\/1756285615605700.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s004150050142","article-title":"Prognosis of myasthenia gravis: a retrospective study of 380 patients","volume":"244","author":"Cosi V","year":"1997","unstructured":"Cosi V Romani A Lombardi M Prognosis of myasthenia gravis: a retrospective study of 380 patients. J Neurol 1997;244(9):548\u2013555. doi:10.1007\/s004150050142.","journal-title":"J Neurol"},{"issue":"1","key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth GS","year":"2000","unstructured":"Gronseth GS Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55(1):7\u201315. doi:10.1212\/WNL.55.1.7.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie GO","year":"2010","unstructured":"Skeie GO Apostolski S Evoli A Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17(7):893\u2013902. doi:10.1111\/j.1468-1331.2010.03019.x.","journal-title":"Eur J Neurol"},{"issue":"6","key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","unstructured":"Wolfe GI Kaminski HJ Aban IB Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016;375(6):511\u2013522. doi:10.1056\/NEJMoa1602489.","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_3_1_76_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2005.01.002","article-title":"Myasthenia gravis: management issues during pregnancy","volume":"121","author":"Ferrero S","year":"2005","unstructured":"Ferrero S Pretta S Nicoletti A Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;121(2):129\u2013138. doi:10.1016\/j.ejogrb.2005.01.002.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group","volume":"85","author":"Norwood F","year":"2014","unstructured":"Norwood F Dhanjal M Hill M Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 2014;85(5):538\u2013543. doi:10.1136\/jnnp-2013-305572.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologist\u2019s management guidelines","volume":"15","author":"Sussman J","year":"2015","unstructured":"Sussman J Farrugia ME Maddison P Myasthenia gravis: Association of British Neurologist\u2019s management guidelines. Pract Neurol 2015;15(3):199\u2013206. doi:10.1136\/practneurol-2015-001126.","journal-title":"Pract Neurol"},{"issue":"8","key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/(SICI)1097-4598(199608)19:8<959::AID-MUS4>3.0.CO;2-7","article-title":"Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis","volume":"19","author":"Jonkers I","year":"1996","unstructured":"Jonkers I Swerup C Pirskanen R Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis. Muscle Nerve 1996;19(8):959\u2013965. doi:10.1002\/(SICI)1097-4598(199608)19:8<959::AID-MUS4>3.0.CO;2-7.","journal-title":"Muscle Nerve"},{"issue":"1","key":"e_1_3_1_80_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12035-014-8887-2","article-title":"Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome","volume":"52","author":"Tarr TB","year":"2015","unstructured":"Tarr TB Wipf P Meriney SD. Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome. Mol Neurobiol 2015;52(1):456\u2013463. doi:10.1007\/s12035-014-8887-2.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"e_1_3_1_81_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz PW","year":"2003","unstructured":"Wirtz PW Nijnuis MG Sotodeh M The epidemiology of myasthenia gravis, Lambert-eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250(6):698\u2013701. doi:10.1007\/s00415-003-1063-7.","journal-title":"J Neurol"},{"issue":"3","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O\u2019Neill JH","year":"1988","unstructured":"O\u2019Neill JH Murray NM Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111(Pt 3):577\u2013596. doi:10.1093\/brain\/111.3.577.","journal-title":"Brain"},{"issue":"1","key":"e_1_3_1_83_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JTO.0b013e3181c3f4f1","article-title":"Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer","volume":"5","author":"Payne M","year":"2010","unstructured":"Payne M Bradbury P Lang B Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010;5(1):34\u201338. doi:10.1097\/JTO.0b013e3181c3f4f1.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_1_84_2","first-page":"973808","article-title":"Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus NE","year":"2011","unstructured":"Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis 2011;2011:973808. doi:10.4061\/2011\/973808.","journal-title":"Autoimmune Dis"},{"issue":"12","key":"e_1_3_1_85_2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer MJ","year":"2011","unstructured":"Titulaer MJ Lang B Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10(12):1098\u20131107. doi:10.1016\/S1474-4422(11)70245-9.","journal-title":"Lancet Neurol"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.025"},{"issue":"7","key":"e_1_3_1_87_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer MJ","year":"2011","unstructured":"Titulaer MJ Maddison P Sont JK Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011;29(7):902\u2013908. doi:10.1200\/JCO.2010.32.0440.","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_1_88_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.nmd.2006.05.009","article-title":"Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis","volume":"16","author":"Baslo MB","year":"2006","unstructured":"Baslo MB Deymeer F Serdaroglu P Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis. Neuromuscul Disord 2006;16(7):454\u2013458. doi:10.1016\/j.nmd.2006.05.009.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"e_1_3_1_89_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mus.880170906","article-title":"Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome","volume":"17","author":"Tim RW","year":"1994","unstructured":"Tim RW Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994;17(9):995\u20131001. doi:10.1002\/mus.880170906.","journal-title":"Muscle Nerve"},{"key":"e_1_3_1_90_2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim RW","year":"1998","unstructured":"Tim RW Massey JM Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 1998;841:823\u2013826. doi:10.1111\/j.1749-6632.1998.tb11024.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"e_1_3_1_91_2","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jnnp.54.9.764","article-title":"Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients","volume":"54","author":"Elrington GM","year":"1991","unstructured":"Elrington GM Murray NM Spiro SG Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991;54(9):764\u2013767. doi:10.1136\/jnnp.54.9.764.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"e_1_3_1_92_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS task force","volume":"18","author":"Titulaer MJ","year":"2011","unstructured":"Titulaer MJ Soffietti R Dalmau J Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19\u2013e3. doi:10.1111\/j.1468-1331.2010.03220.x.","journal-title":"Eur J Neurol"},{"issue":"3","key":"e_1_3_1_93_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/21678707.2014.887464","article-title":"3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome","volume":"2","author":"Lindquist S","year":"2014","unstructured":"Lindquist S Stangel M. 3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome. Expert Opin Orphan Drugs 2014;2(3):293\u2013300. doi:10.1517\/21678707.2014.887464.","journal-title":"Expert Opin Orphan Drugs"},{"key":"e_1_3_1_94_2","first-page":"341","article-title":"Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine","volume":"7","author":"Lindquist S","year":"2011","unstructured":"Lindquist S Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 2011;7:341\u2013349. doi:10.2147\/NDT.S10464.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"e_1_3_1_95_2","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","author":"Keogh M","year":"2011","unstructured":"Keogh M Sedehizadeh S Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;(2):CD003279. doi:10.1002\/14651858.CD003279.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"e_1_3_1_96_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00415-009-5442-6","article-title":"3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study","volume":"257","author":"Flet L","year":"2010","unstructured":"Flet L Polard E Guillard O 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010;257(6):937\u2013946. doi:10.1007\/s00415-009-5442-6.","journal-title":"J Neurol"},{"issue":"1","key":"e_1_3_1_97_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz PW","year":"2009","unstructured":"Wirtz PW Verschuuren JJ van Dijk JG Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86(1):44\u201348. doi:10.1038\/clpt.2009.35.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"e_1_3_1_98_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","article-title":"Available treatment options for the management of Lambert-Eaton myasthenic syndrome","volume":"7","author":"Verschuuren JJ","year":"2006","unstructured":"Verschuuren JJ Wirtz PW Titulaer MJ Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7(10):1323\u20131336. doi:10.1517\/14656566.7.10.1323","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"e_1_3_1_99_2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk CH","year":"1990","unstructured":"Chalk CH Murray NM Newsom-Davis J Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40(10):1552\u20131556. doi:10.1212\/WNL.40.10.1552.","journal-title":"Neurology"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.024"},{"issue":"1","key":"e_1_3_1_101_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz PW","year":"2005","unstructured":"Wirtz PW Lang B Graus F P\/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005;164(1\u20132):161\u2013165. doi:10.1016\/j.jneuroim.2005.04.001.","journal-title":"J Neuroimmunol"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201612000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:58:35Z","timestamp":1752155915000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1212\/CON.0000000000000415"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000415","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}